Mutual of America Capital Management LLC Has $18.26 Million Stake in Boston Scientific Corporation $BSX

Mutual of America Capital Management LLC trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 1.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 169,986 shares of the medical equipment provider’s stock after selling 1,783 shares during the period. Mutual of America Capital Management LLC’s holdings in Boston Scientific were worth $18,258,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in shares of Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after buying an additional 3,932 shares during the period. MRA Advisory Group bought a new stake in Boston Scientific during the second quarter valued at about $273,000. Bank of New Hampshire grew its position in shares of Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd increased its stake in shares of Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after purchasing an additional 5,704 shares during the period. Finally, New England Research & Management Inc. acquired a new position in shares of Boston Scientific during the 2nd quarter worth about $1,133,000. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Edward J. Ludwig sold 4,000 shares of the business’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Evercore ISI lowered their target price on Boston Scientific from $115.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. Canaccord Genuity Group increased their price objective on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Truist Financial boosted their target price on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Wells Fargo & Company upped their target price on shares of Boston Scientific from $118.00 to $124.00 and gave the company an “overweight” rating in a research note on Thursday, July 24th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $120.71.

Boston Scientific Stock Up 1.5%

Shares of BSX stock opened at $99.20 on Friday. The stock has a market cap of $146.99 billion, a P/E ratio of 59.05, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The stock has a fifty day moving average price of $101.29 and a 200 day moving average price of $101.75. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.